[{"id":"00386017-fdba-4646-91db-e52d18a56ce7","acronym":"PEPN2011","url":"https://clinicaltrials.gov/study/NCT04851119","created_at":"2021-04-20T14:55:40.726Z","updated_at":"2024-07-02T16:35:08.278Z","phase":"Phase 1/2","brief_title":"Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors","source_id_and_acronym":"NCT04851119 - PEPN2011","lead_sponsor":"Children's Oncology Group","biomarkers":" RNF43 • CTNNB1 • TCF7L2","pipe":" | ","alterations":" APC mutation • CTNNB1 mutation • RNF43 mutation • CTNNB1 S45P","tags":["RNF43 • CTNNB1 • TCF7L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation • CTNNB1 mutation • RNF43 mutation • CTNNB1 S45P"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tegavivint (BC2059)"],"overall_status":"Recruiting","enrollment":" Enrollment 147","initiation":"Initiation: 11/08/2021","start_date":" 11/08/2021","primary_txt":" Primary completion: 06/30/2028","primary_completion_date":" 06/30/2028","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2024-04-22"},{"id":"4c415dce-6421-46bd-97fd-5cc700ebf780","acronym":"","url":"https://clinicaltrials.gov/study/NCT05797805","created_at":"2023-04-04T16:04:03.714Z","updated_at":"2024-07-02T16:35:18.401Z","phase":"Phase 1/2","brief_title":"A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma","source_id_and_acronym":"NCT05797805","lead_sponsor":"Iterion Therapeutics","biomarkers":" AXIN1","pipe":" | ","alterations":" CTNNB1 mutation","tags":["AXIN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTNNB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • tegavivint (BC2059)"],"overall_status":"Recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 09/13/2023","start_date":" 09/13/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-02-21"},{"id":"300dc214-2f53-46f4-88db-099cbeecb27f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05755087","created_at":"2023-03-06T15:01:37.165Z","updated_at":"2024-07-02T16:35:24.905Z","phase":"Phase 1","brief_title":"Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma","source_id_and_acronym":"NCT05755087","lead_sponsor":"Lapo Alinari","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" BCL2 expression • MYC expression • MYC translocation • MYC translocation + BCL2 translocation • BCL2 translocation","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression • MYC translocation • MYC translocation + BCL2 translocation • BCL2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tegavivint (BC2059)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/06/2023","start_date":" 03/06/2023","primary_txt":" Primary completion: 03/05/2027","primary_completion_date":" 03/05/2027","study_txt":" Completion: 03/05/2027","study_completion_date":" 03/05/2027","last_update_posted":"2023-12-29"},{"id":"a57663a3-200f-4a64-8df5-537b7c4835d2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04780568","created_at":"2023-12-11T17:16:35.473Z","updated_at":"2024-07-02T16:35:26.635Z","phase":"Phase 1","brief_title":"Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04780568","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" EGFR • NOTCH3","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I","tags":["EGFR • NOTCH3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • tegavivint (BC2059)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/18/2022","start_date":" 01/18/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-12-11"}]